Table 2

Tumor and patient characteristics of the 67 tumors used for MSI and array CGH analysis.

ID

gender

age

Tumor type

T

N

origin

MSI status

Cluster number

Cluster order

% events

% gains

% losses


1

F

62

intestinal

T2

N1

Cauc SA

MSS

5

34

3.2

3.2

0

2

M

73

intestinal

T2

N2

Cauc SA

MSS

5

28

16.9

13.4

3.4

3

F

59

intestinal

T2

N1

Cauc SA

MSS

5

26

26.5

15.1

11.4

4

F

74

intestinal

T2

N1

Cauc SA

MSS

5

27

15.7

9.3

6.5

5

M

56

intestinal

T3

N1

Cauc SA

MSI

-

-

15.6

10.3

5.3

6

M

57

intestinal

T2

N1

Cauc SA

MSS

6

48

3.4

2.4

1.0

7

F

84

intestinal

T1

N0

Cauc SA

MSS

6

43

10.9

7.9

3.1

8

F

79

intestinal

T3

N0

Cauc SA

MSI

-

-

17.6

16.8

0.8

9

M

68

intestinal

T3

N2

Cauc SA

MSS

5

25

32.1

24.3

7.7

10

M

65

intestinal

T2

N0

native SA

MSI

-

-

1.7

1.7

0

11

M

57

intestinal

T1

N0

native SA

MSI

-

-

0

0

0

12

F

29

intestinal

T4

N0

native SA

MSS

6

37

28.3

26.2

2.1

13

F

59

intestinal

T3

N1

native SA

MSS

6

42

10.6

5.3

5.3

14

M

66

intestinal

T2

N1

native SA

MSS

5

31

6.4

6.4

0

15

M

46

intestinal

T3

N2

native SA

MSS

5

35

3.2

3.2

0

16

F

-

diffuse

T4

N2

native SA

MSS

6

44

13.2

12.4

0.7

17

M

51

intestinal

T3

N1

native SA

MSS

5

32

6.1

6.1

0

18

F

49

intestinal

T3

N1

native SA

MSS

4

20

29.1

18.2

10.9

19

M

56

intestinal

T3

N1

native SA

MSS

4

19

26.0

10.3

15.7

20

M

48

intestinal

T3

N2

native SA

MSS

5

36

5.4

5.4

0

21

M

65

mixed

T3

N1

native SA

MSI

-

-

18.2

16.3

1.9

22

M

60

intestinal

T2

-

native SA

MSS

6

41

14.0

11.3

2.7

23

F

63

intestinal

-

-

native SA

MSS

6

38

17.1

10.7

6.4

24

F

54

papillary

T2

N0

native SA

MSS

3

14

44.8

20.6

24.2

25

M

67

intestinal

T3

N1

native SA

MSS

-

-

-

-

-

26

M

31

intestinal

T3

N1

native SA

MSS

5

24

41.1

28.4

12.7

27

M

43

intestinal

T3

N1

native SA

MSI

-

-

9.9

9.9

0

28

F

71

intestinal

T3

-

native SA

MSS

5

33

3.7

2.7

1.0

29

F

77

intestinal

T3

N1

native SA

MSS

5

30

12.7

7.1

5.5

30

M

57

intestinal

T2

N0

native SA

MSS

-

-

-

-

-

31

M

79

intestinal

T3

N2

native SA

MSI

-

-

2.5

2.5

0

32

M

57

intestinal

T4

N0

native SA

MSI

-

-

17.8

16.8

1.0

33

M

56

mixed

T3

N1

native SA

MSS

4

17

42.2

21.3

20.9

34

F

49

mixed

T3

N3

native SA

MSS

5

29

22.3

19.2

3.2

35

F

82

diffuse

T1

N0

UK

MSS

6

46

11.2

10.3

1.0

36

M

81

diffuse

T3

N2

UK

MSS

4

22

15.7

7.2

8.5

37

M

71

diffuse

T2

N1

UK

MSS

7

53

18.4

14.7

3.7

38

M

73

intestinal

T2

N0

UK

MSS

2

11

26.0

17.2

8.8

39

F

65

diffuse

T2

N3

UK

MSS

6

45

15.0

12.0

3.1

40

F

58

diffuse

T3

N3

UK

MSS

1

6

25.7

13.7

12.0

41

F

51

diffuse

T3

N3

UK

MSS

1

7

22.4

16.5

6.0

42

M

91

intestinal

T1

N0

UK

MSS

7

56

49.2

27.6

21.6

43

M

71

diffuse

T3

N2

UK

MSS

7

49

40.6

19.8

20.8

44

M

73

intestinal

T2

N1

UK

MSS

1

5

21.0

8.2

12.9

45

M

64

diffuse

T2

N0

UK

MSS

7

50

14.9

10.3

4.6

46

F

71

intestinal

T1

N0

UK

MSS

1

4

40.8

13.4

27.4

47

F

60

intestinal

T4

N1

UK

MSS

3

16

30.1

15.6

14.5

48

F

96

diffuse

T3

N0

UK

MSS

2

12

41.0

25.0

16.0

49

M

91

mixed

T3

N0

UK

MSS

6

40

16.0

11.4

4.6

50

M

81

diffuse

T2

N0

UK

MSS

2

10

37.7

17.2

20.4

51

F

83

intestinal

T2

N0

UK

MSS

7

51

14.5

10.5

4.0

52

F

82

intestinal

T3

N1

UK

MSS

6

47

2.2

2.2

0

53

F

77

intestinal

T3

N1

UK

MSS

6

39

19.5

11.1

8.5

54

M

74

mixed

T2

N1

UK

MSS

2

8

44.8

22.4

22.3

55

F

59

diffuse

T3

N1

UK

MSS

3

15

26.4

18.1

8.2

56

M

77

mixed

T3

N2

UK

MSS

1

3

24.1

13.7

10.3

57

M

75

intestinal

T2

N0

UK

MSS

2

9

36.9

18.2

18.7

58

M

64

diffuse

T3

N3

UK

MSS

2

13

35.3

20.2

15.1

59

M

71

intestinal

T3

N1

UK

MSS

1

2

31.0

11.7

19.3

60

F

74

diffuse

T3

N2

UK

MSS

4

23

23.2

14.7

8.4

61

M

81

intestinal

T2

N0

UK

MSI

-

-

10.7

8.7

2.0

62

F

74

mixed

T3

N2

UK

MSS

4

18

30.4

17.9

12.5

63

M

67

mixed

T3

N1

UK

MSS

7

52

12.3

6.4

5.9

64

M

73

intestinal

T3

N1

UK

MSS

4

21

15.2

7.3

7.9

65

F

66

mixed

T3

N2

UK

MSS

7

55

34.3

18.7

15.6

66

M

82

intestinal

T1

N1

UK

MSS

7

54

46.7

27.4

19.3

67

F

62

mixed

T3

N0

UK

MSS

1

1

44.0

20.7

23.3


Percentages of events, gains and losses are given for all tumors of sufficient array CGH quality. Cluster number and order are listed for the 56 cases included in the cluster analysis.

F: female, M: male, T: T-stage, N: N-stage MSS: microsatellite stable, MSI: microsatellite instable, Cauc SA: Caucasian South African patients, native SA: native South African patients, UK: patients from United Kingdom, -: unknown.

Buffart et al. BMC Medical Genomics 2011 4:7   doi:10.1186/1755-8794-4-7

Open Data